Revisiting nonclassical HLA II functions in antigen presentation: Peptide editing and its modulation.
CD4+ T cell epitope
HLA-DM
HLA-DO
MHC class II
nonclassical MHCII
peptide editing
peptidome
Journal
HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
04
08
2020
accepted:
04
08
2020
pubmed:
9
8
2020
medline:
28
5
2021
entrez:
9
8
2020
Statut:
ppublish
Résumé
The nonclassical major histocompatibility complex of class II molecules (ncMHCII) HLA-DM (DM) and HLA-DO (DO) feature essential functions for the selection of the peptides that are displayed by classical MHCII proteins (MHCII) for CD4
Substances chimiques
HLA-D Antigens
0
Histocompatibility Antigens Class II
0
Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
415-429Informations de copyright
© 2020 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.
Références
Harding CV, Unanue ER. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature. 1990;346:574-576.
Demotz S, Grey HM, Sette A. The minimal number of class II MHC-antigen complexes needed for T cell activation. Science. 1990;249:1028-1030.
Chen X, Laur O, Kambayashi T, et al. Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development. J Exp Med. 2002;195:1053-1062.
Karlsson L, Surh CD, Sprent J, Peterson PA. A novel class II MHC molecule with unusual tissue distribution. Nature. 1991;351:485-488.
Kasahara M. The chromosomal duplication model of the major histocompatibility complex. Immunol Rev. 1999;167:17-32.
Hughes AL, Hughes MK, Howell CY, Nei M. Natural selection at the class II major histocompatibility complex loci of mammals. Philos Trans R Soc Lond B Biol Sci. 1994;346:359-366; discussion 366-7.
Fumagalli M, Sironi M, Pozzoli U, Ferrer-Admettla A, Pattini L, Nielsen R. Signatures of environmental genetic adaptation pinpoint pathogens as the main selective pressure through human evolution. PLoS Genet. 2011;7:e1002355.
Álvaro-Benito M, Wieczorek M, Sticht J, Kipar C, Freund C. HLA-DMA polymorphisms differentially affect MHC class II peptide loading. J Immunol. 2014;194:803-816. https://doi.org/10.4049/jimmunol.1401389.
Álvaro-Benito M, Morrison E, Ebner F, et al. Distinct editing functions of natural HLA-DM allotypes impact antigen presentation and CD4+ T cell activation. Cell Mol Immunol. 2018;17:133-142. https://doi.org/10.1038/s41423-018-0181-1.
Denzin LK, Khan AA, Virdis F, et al. Neutralizing antibody responses to viral infections are linked to the non-classical MHC class II gene H2-Ob. Immunity. 2017;47:310-322.
Lokki M, Paakkanen R. The complexity and diversity of MHC challenge disease association studies. HLA. 2019;93(1):3-15.
Linjama T, Räther C, Ritari J, et al. Extended HLA haplotypes and their impact on DPB1 matching of unrelated hematologic stem cell transplant donors. Biol Blood Marrow Transplant. 2019;25:1956-1964.
Hirata J, Hosomichi K, Sakaue S, et al. Genetic and phenotypic landscape of the major histocompatibilty complex region in the Japanese population. Nat Genet. 2019;51:470-480.
Fleischhauer K, Shaw BE, Gooley T, et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol. 2012;13:366-374.
Solomon SR, Aubrey MT, Zhang X, et al. Selecting the best donor for Haploidentical transplant: impact of HLA, killer cell immunoglobulin-like receptor genotyping, and other clinical variables. Biol Blood Marrow Transplant. 2018;24:789-798.
Djilali-Saiah I, Benini V, Daniel S, Assan R, Bach JF, Caillat-Zucman S. Linkage disequilibrium between HLA class II (DR, DQ, DP) and antigen processing (LMP, TAP, DM) genes of the major histocompatibility complex. Tissue Antigens. 1996;48:87-92.
LeibundGut-Landmann S, Waldburger JM, Krawczyk M, et al. Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol. 2004;34:1513-1525.
Walter W, Scheuer C, Lingnau K, et al. H2-M, a facilitator of MHC class II peptide loading, and its negative modulator H2-O are differentially expressed in response to proinflammatory cytokines. Immunogenetics. 2000;51:794-804.
Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31:443-473.
Denzin LK, Cresswell P. HLA-DM induces clip dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell. 1995;82:155-165.
Hornell TMC, Burster T, Jahnsen FL, et al. Human dendritic cell expression of HLA-DO is subset specific and regulated by maturation. J Immunol. 2006;176:3536-3547.
Lee J, Tam H, Adler L, Ilstad-Minnihan A, Macaubas C, Mellins ED. The MHC class II antigen presentation pathway in human monocytes differs by subset and is regulated by cytokines. PLoS One. 2017;12:e0183594.
Miller MA, Ganesan APV, Luckashenak N, Mendonca M, Eisenlohr LC. Endogenous antigen processing drives the primary CD4+ T cell response to influenza. Nat Med. 2015;21:1216-1222.
Lindner R, Unanue ER. Distinct antigen MHC class II complexes generated by separate processing pathways. EMBO J. 1996;15:6910-6920.
Pu Z, Lovitch SB, Bikoff EK, Unanue ER. T cells distinguish MHC-peptide complexes formed in separate vesicles and edited by H2-DM. Immunity. 2004;20:467-476.
Mohan JF, Petzold SJ, Unanue ER. Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med. 2011;208:2375-2383.
Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc Natl Acad Sci U S A. 1999;96:15050-15055.
Patterson NL, Mintern JD. Intersection of autophagy with pathways of antigen presentation. Protein Cell. 2012;3:911-920.
Zeng F, Morelli AE. Extracellular vesicle-mediated MHC cross-dressing in immune homeostasis, transplantation, infectious diseases, and cancer. Semin Immunopathol. 2018;40:477-490.
Anczurowski M, Sugata K, Matsunaga Y, et al. Chaperones of the class I peptide-loading complex facilitate the constitutive presentation of endogenous antigens on HLA-DP84GGPM87. J Autoimmun. 2019;102:114-125.
Miller MA, Ganesan APV, Eisenlohr LC. Toward a network model of MHC class II-restricted antigen processing. Front Immunol. 2013;4:464.
Veerappan Ganesan AP, Eisenlohr LC. The elucidation of non-classical MHC class II antigen processing through the study of viral antigens. Curr Opin Virol. 2017;22:71-76.
Wieczorek M, Abualrous ET, Sticht J, et al. Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol. 2017;8:292.
Pos W, Sethi DK, Call MJ, et al. Crystal structure of the HLA-DM-HLA-DR1 complex defines mechanisms for rapid peptide selection. Cell. 2012;151:1557-1568.
Fortin J-S, Cloutier M, Thibodeau J. Exposing the specific roles of the invariant chain isoforms in shaping the MHC class II peptidome. Front Immunol. 2013;4:443.
Sette A, Southwood S, Miller J, Appella E. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med. 1995;181:677-683.
Gunther S, Schlundt A, Sticht J, et al. Bidirectional binding of invariant chain peptides to an MHC class II molecule. Proc Natl Acad Sci U S A. 2010;107:22219-22224.
Doyle HA, Mamula MJ. Autoantigenesis: the evolution of protein modifications in autoimmune disease. Curr Opin Immunol. 2012;24:112-118.
Weber DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science. 1996;274:618-621.
Belmares MP, Busch R, Wucherpfennig KW, McConnell HM, Mellins ED. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J Immunol. 2002;169:5109-5117.
Doebele RC, Busch R, Scott HM, Pashine A, Mellins ED. Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity. 2000;13:517-527.
Hou T, Macmillan H, Chen Z, et al. An insertion mutant in DQA1*0501 restores susceptibility to HLA-DM: implications for disease associations. J Immunol. 2011;187:2442-2452.
Chou C-L, Sadegh-Nasseri S. Hla-Dm recognizes the flexible conformation of major histocompatibility complex class II. J Exp Med. 2000;192:1697-1706.
Stratikos E, Wiley DC, Stern LJ. Enhanced catalytic action of HLA-DM on the exchange of peptides lacking backbone hydrogen bonds between their N-terminal region and the MHC class II α-chain. J Immunol. 2004;172:1109-1117.
Anders A-K, Call MJ, Schulze MSED, et al. HLA-DM captures partially empty HLA-DR molecules for catalyzed removal of peptide. Nat Immunol. 2011;12:54-61.
Yin L, Trenh P, Guce A, et al. Susceptibility to HLA-DM protein is determined by a dynamic conformation of major histocompatibility complex class II molecule bound with peptide. J Biol Chem. 2014;289:23449-23464.
Wieczorek M, Sticht J, Stolzenberg S, et al. MHC class II complexes sample intermediate states along the peptide exchange pathway. Nat Commun. 2016;7:13224.
van Lith M, McEwen-Smith RM, Benham AM. HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM. J Biol Chem. 2010;285:40800-40808.
Mellins E, Smith L, Arp B, Cotner T, Celis E, Pious D. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature. 1990;343:71-74.
Morris P, Shaman J, Attaya M, et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature. 1994;368:551-554.
Fling SP, Arp B, Pious D. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature. 1994;368:554-558.
Denzin LK, Robbins NF, Carboy-Newcomb C, Cresswell P. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity. 1994;1:595-606.
Sloan VS, Cameron P, Porter G, et al. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature. 1995;375:802-806.
Schafer PH, Green JM, Malapati S, Gu L, Pierce K. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes. J Immunol. 1996;157:5487-5495.
Vogt AB, Kropshofer H, Moldenhauer G, Hämmerling GJ. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl Acad Sci U S A. 1996;93:9724-9729.
Kropshofer H, Arndt SO, Moldenhauer G, Hämmerling GJ, Vogt AB. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity. 1997;6:293-302.
Nicholson MJ, Moradi B, Seth NP, et al. Small molecules that enhance the catalytic efficiency of HLA-DM. J Immunol. 2006;176:4208-4220.
Fremont DH, Crawford F, Marrack P, Hendrickson WA, Kappler J. Crystal structure of mouse H2-M. Immunity. 1998;9:385-393.
Pashine A, Busch R, Belmares MP, et al. Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity. 2003;19:183-192.
Busch R, Reich Z, Zaller DM, Sloan V, Mellins ED. Secondary structure composition and pH-dependent conformational changes of soluble recombinant HLA-DM. J Biol Chem. 1998;273:27557-27564.
Potter PK, Copier J, Sacks SH, et al. Accurate intracellular localization of HLA-DM requires correct spacing of a cytoplasmic YTPL targeting motif relative to the transmembrane domain. Eur J Immunol. 1999;29:3936-3944.
Pierre P, Denzin LK, Hammond C, et al. HLA-DM is localized to conventional and unconventional MHC class II-containing endocytic compartments. Immunity. 1996;4:229-239.
Arndt SO, Vogt AB, Markovic-Plese S, et al. Functional HLA-DM on the surface of B cells and immature dendritic cells. EMBO J. 2000;19:1241-1251.
Pezeshki AM, Côté MH, Azar GA, Routy JP, Boulassel MR, Thibodeau J. Forced expression of HLA-DM at the surface of dendritic cells increases loading of synthetic peptides on MHC class II molecules and modulates T cell responses. J Immunol. 2011;187:74-81.
Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hämmerling GJ. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J. 1996;15:6144-6154.
Muntasell A, Carrascal M, Serradell L, et al. HLA-DR4 molecules in neuroendocrine epithelial cells associate to a heterogeneous repertoire of cytoplasmic and surface self peptides. J Immunol. 2002;169:5052-5060.
Muntasell A, Carrascal M, Alvarez I, et al. Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands. J Immunol. 2004;173:1085-1093.
Álvaro-Benito M, Morrison E, Abualrous ET, Kuropka B, Freund C. Quantification of HLA-DM-dependent major histocompatibility complex of class II immunopeptidomes by the peptide landscape antigenic epitope alignment utility. Front Immunol. 2018;9:872.
Zhou Z, Reyes-Vargas E, Escobar H, et al. Peptidomic analysis of type 1 diabetes associated HLA-DQ molecules and the impact of HLA-DM on peptide repertoire editing. Eur J Immunol. 2017;47:314-326.
Abelin JG, Harjanto D, Malloy M, et al. Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction. Immunity. 2019;51:766-779.
Liljedahl M, Kuwana T, Fung-Leung WP, Jackson MR, Peterson PA, Karlsson L. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J. 1996;15:4817-4824.
Deshaies F, Brunet A, Diallo DA, Denzin LK, Samaan A, Thibodeau J. A point mutation in the groove of HLA-DO allows egress from the endoplasmic reticulum independent of HLA-DM. Proc Natl Acad Sci U S A. 2005;102:6443-6448.
Denzin LK, Sant'Angelo DB, Hammond C, Surman MJ, Cresswell P. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science. 1997;278:106-109.
Kropshofer H, Vogt AB, Thery C, et al. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J. 1998;17:2971-2981.
Guce AI, Mortimer SE, Yoon T, et al. HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. Nat Struct Mol Biol. 2013;20:90-98.
Poluektov YO, Kim A, Hartman IZ, Sadegh-Nasseri S. HLA-DO as the optimizer of epitope selection for MHC class II antigen presentation. PLoS One. 2013;8:e71228.
Hammond C, Denzin LK, Pan M, Griffith JM, Geuze HJ, Cresswell P. The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, −DM, and -DO molecules. J Immunol. 1998;161:3282-3291.
Gondré-Lewis TA, Moquin AE, Drake JR. Prolonged antigen persistence within nonterminal late endocytic compartments of antigen-specific B lymphocytes. J Immunol. 2001;166:6657-6664.
van Lith M, van Ham M, Griekspoor A, et al. Regulation of MHC class II antigen presentation by sorting of recycling HLA-DM/DO and class II within the multivesicular body. J Immunol. 2001;167:884-892.
Brunet A, Samaan A, Deshaies F, Kindt TJ, Thibodeau J. Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-DObeta. J Biol Chem. 2000;275:37062-37071.
Denzin LK, Cresswell P. Sibling rivalry: competition between MHC class II family members inhibits immunity. Nat Struct Mol Biol. 2013;20:7-10.
Nanaware PP, Jurewicz MM, Leszyk J, Shaffer SA, Stern LJ. HLA-DO modulates the diversity of the MHC-II self-peptidome. Mol Cell Proteomics. 2018;18:490-503.
Alfonso C, Williams GS, Han JO, Westberg JA, Winqvist O, Karlsson L. Analysis of H2-O influence on antigen presentation by B cells. J Immunol. 2003;171:2331-2337.
Yoon T, Macmillan H, Mortimer SE, et al. Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesis. Proc Natl Acad Sci U S A. 2012;109:11276-11281.
Deshaies F, Diallo DA, Fortin JS, et al. Evidence for a human leucocyte antigen-DM-induced structural change in human leucocyte antigen-DOβ. Immunology. 2009;127:408-417.
Glazier KS, Hake SB, Tobin HM, Chadburn A, Schattner EJ, Denzin LK. Germinal center B cells regulate their capability to present antigen by modulation of HLA-DO. J Exp Med. 2002;195:1063-1069.
Draghi NA, Denzin LK. H2-O, a MHC class II-like protein, sets a threshold for B-cell entry into germinal centers. Proc Natl Acad Sci U S A. 2010;107:16607-16612.
Falk K, Lau JM, Santambrogio L, et al. Ligand exchange of major histocompatibility complex class II proteins is triggered by H-bond donor groups of small molecules. J Biol Chem. 2002;277:2709-2715.
Marin-Esteban V, Falk K, Rötzschke O. Small-molecular compounds enhance the loading of APC with encephalitogenic MBP protein. J Autoimmun. 2003;20:63-69.
Höpner S, Dickhaut K, Hofstätter M, et al. Small organic compounds enhance antigen loading of class II major histocompatibility complex proteins by targeting the polymorphic P1 pocket. J Biol Chem. 2006;281:38535-38542.
Call MJ, Xing X, Cuny GD, et al. In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. J Immunol. 2009;162:4030-4036.
Illing PT, Vivian JP, Purcell AW, Rossjohn J, McCluskey J. Human leukocyte antigen-associated drug hypersensitivity. Curr Opin Immunol. 2013;25:81-89.
Alvaro-Benito M, Morrison E, Wieczorek M, Sticht J, Freund C. Human leukocyte Antigen-DM polymorphisms in autoimmune diseases. Open Biol. 2016;6:160165.
Miyazaki T, Wolf P, Tourne S, et al. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell. 1996;84:531-541.
Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, van Kaer L. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell. 1996;84:543-550.
Fung-Leung WP, Surh CD, Liljedahl M, et al. Antigen presentation and T cell development in H2-M-deficient mice. Science. 1996;271:1278-1281.
Wolf PR, Tourne S, Miyazaki T, Benoist C, Mathis D, Ploegh HL. The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed. Eur J Immunol. 1998;28:2605-2618.
Bikoff EK, Wutz G, Kenty GA, Koonce CH, Robertson EJ. Relaxed DM requirements during class II peptide loading and CD4+ T cell maturation in BALB/c mice. J Immunol. 2001;166:5087-5098.
Koonce CH, Wutz G, Robertson EJ, Vogt AB, Kropshofer H, Bikoff EK. DM loss in k haplotype mice reveals isotype-specific chaperone requirements. J Immunol. 2003;170:3751-3761.
Wong J, Obst R, Correia-Neves M, Losyev G, Mathis D, Benoist C. Adaptation of TCR repertoires to self-peptides in regulatory and nonregulatory CD4+ T cells. J Immunol. 2007;178:7032-7041.
Morgan MAJ, Muller PSS, Mould A, et al. The nonconventional MHC class II molecule DM governs diabetes susceptibility in NOD mice. PLoS One. 2013;8:e56738.
Liljedahl M, Winqvist O, Surh CD, et al. Altered antigen presentation in mice lacking H2-O. Immunity. 1998;8:233-243.
Perraudeau M, Taylor P R, Stauss H J, et al. Altered major histocompatibility complex class II peptide loading in H2-O-deficient mice. Eur J Immunol. 2000;30:2871-2880.
Yi W, Seth NP, Martillotti T, Wucherpfennig KW, Sant'Angelo DB, Denzin LK. Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence. J Clin Invest. 2010;120:1324-1336.
Lee DS, Curie A, Ernst B, Sprent J, Surh CD. Thymic selection by a single MHC/peptide ligand: autoreactive T cells are low-affinity cells. Immunity. 1999;10:83-92.
Mendiratta SK, Kovalik JP, Hong S, Singh N, Martin WD, van Kaer L. Peptide dependency of alloreactive CD4+ T cell responses. Int Immunol. 1999;11:351-360.
Felix NJ, Brickey WJ, Griffiths R, et al. H2-DMalpha(−/−) mice show the importance of major histocompatibility complex-bound peptide in cardiac allograft rejection. J Exp Med. 2000;192:31-40.
Nanda NK, Bikoff EK. DM peptide-editing function leads to immunodominance in CD4 T cell responses in vivo. J Immunol. 2005;175:6473-6480.
Menges PR, Jenks SA, Bikoff EK, Friedmann DR, Knowlden ZAG, Sant AJ. An MHC class II restriction bias in CD4 T cell responses toward I-A is altered to I-E in DM-deficient mice. J Immunol. 2008;180:1619-1633.
Nepal RM, Vesosky B, Turner J, Bryant P. DM, but not cathepsin L, is required to control an aerosol infection with Mycobacterium tuberculosis. J Leukoc Biol. 2008;84:1011-1018.
Tourne S, Miyazaki T, Oxenius A, et al. Selection of a broad repertoire of CD4+ T cells in H-2Ma0/0 mice. Immunity. 1997;7:187-195.
Alfonso C, Han J-O, Williams GS, Karlsson L. The impact of H2-DM on humoral immune responses. J Immunol. 2001;167:6348-6355.
Okada Y, Suzuki A, Ikari K, et al. Contribution of a non-classical HLA gene, HLA-DOA, to the risk of rheumatoid arthritis. Am J Hum Genet. 2016;99:366-374.
Raj P, Rai E, Song R, et al. Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity. Elife. 2016;5:e12089.
Sirota M, Schaub MA, Batzoglou S, Robinson WH, Butte AJ. Autoimmune disease classification by inverse association with SNP alleles. PLoS Genet. 2009;5:e1000792.
Chen H, Yao Y, Wang Y, et al. Polymorphisms of HLA-DM on treatment response to interferon/ribavirin in patients with chronic hepatitis C virus type 1 infection. Int J Environ Res Public Health. 2016;13:1030.
Fadista J, Manning AK, Florez JC, Groop L. The (in)famous GWAS P-value threshold revisited and updated for low-frequency variants. Eur J Hum Genet. 2016;24:1202-1205.
Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, SGE M. IPD-IMGT/HLA Database. Nucleic Acids Res. 2019;48:D948-D955.
Lek M, Karczweski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285-291.